CINECA IRIS Institutional Research Information System

BONORA, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.288
EU - Europa 11.993
AS - Asia 5.045
SA - Sud America 339
AF - Africa 260
OC - Oceania 74
Continente sconosciuto - Info sul continente non disponibili 25
Totale 36.024
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.979
CN - Cina 2.974
IT - Italia 2.088
DK - Danimarca 1.826
IE - Irlanda 1.299
DE - Germania 1.214
SE - Svezia 1.064
FR - Francia 1.019
UA - Ucraina 720
FI - Finlandia 708
GB - Regno Unito 577
KR - Corea 520
SG - Singapore 450
AT - Austria 354
PL - Polonia 299
VN - Vietnam 256
IN - India 233
CA - Canada 210
NL - Olanda 184
ES - Italia 170
BR - Brasile 158
JP - Giappone 125
ZA - Sudafrica 110
ID - Indonesia 96
RO - Romania 84
TW - Taiwan 78
MX - Messico 77
BE - Belgio 75
RU - Federazione Russa 72
TH - Thailandia 68
AU - Australia 64
CH - Svizzera 64
AR - Argentina 51
HK - Hong Kong 49
TR - Turchia 46
CO - Colombia 43
CL - Cile 39
CZ - Repubblica Ceca 35
PE - Perù 32
PK - Pakistan 31
GR - Grecia 29
PT - Portogallo 28
EU - Europa 22
IL - Israele 20
IR - Iran 20
UZ - Uzbekistan 19
NG - Nigeria 17
KE - Kenya 16
UG - Uganda 16
HR - Croazia 15
PH - Filippine 15
SN - Senegal 14
EG - Egitto 12
ET - Etiopia 12
BG - Bulgaria 11
SK - Slovacchia (Repubblica Slovacca) 11
NZ - Nuova Zelanda 10
NO - Norvegia 9
SA - Arabia Saudita 8
TZ - Tanzania 8
EC - Ecuador 7
MU - Mauritius 7
MY - Malesia 7
HU - Ungheria 6
LV - Lettonia 6
MW - Malawi 6
SD - Sudan 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
RS - Serbia 5
CR - Costa Rica 4
CU - Cuba 4
DZ - Algeria 4
JO - Giordania 4
MZ - Mozambico 4
NA - Namibia 4
BO - Bolivia 3
BY - Bielorussia 3
CD - Congo 3
CM - Camerun 3
DO - Repubblica Dominicana 3
EE - Estonia 3
GT - Guatemala 3
KZ - Kazakistan 3
LU - Lussemburgo 3
MD - Moldavia 3
PA - Panama 3
PR - Porto Rico 3
VE - Venezuela 3
AP - ???statistics.table.value.countryCode.AP??? 2
BJ - Benin 2
BT - Bhutan 2
GA - Gabon 2
GH - Ghana 2
IQ - Iraq 2
LI - Liechtenstein 2
LK - Sri Lanka 2
LT - Lituania 2
MO - Macao, regione amministrativa speciale della Cina 2
NP - Nepal 2
Totale 35.999
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.773
Beijing 2.198
Chandler 1.952
Dublin 1.294
Houston 1.188
Fairfield 881
Ashburn 670
Villeurbanne 622
Wilmington 601
Torino 554
Jacksonville 529
Dearborn 479
Medford 469
Princeton 441
Woodbridge 431
Redwood City 384
Seattle 350
Nyköping 314
Vienna 299
Warsaw 285
Cambridge 268
Singapore 268
Pisa 185
Milan 184
Boston 140
New York 134
Turin 132
Fremont 130
Dong Ket 116
Boardman 114
Guangzhou 82
Toronto 79
Verona 75
Shanghai 68
Nanjing 65
San Diego 64
Paris 57
Hangzhou 54
Norwalk 52
Brussels 51
Taipei 51
Munich 50
Rome 50
Hefei 49
Kunming 48
Helsinki 44
São Paulo 43
Los Angeles 42
Nürnberg 38
Washington 38
Chicago 37
Falls Church 35
Jakarta 33
Pune 33
Ottawa 31
Cape Town 30
Jinan 30
Phoenix 30
Santiago 29
Buenos Aires 28
Chengdu 28
Seoul 28
Mountain View 27
London 26
Silver Spring 26
Lima 25
Omaha 24
Bengaluru 23
Brno 23
Lachine 23
Arlington 21
Buffalo 21
Dallas 21
Hebei 21
Montreal 21
Tokyo 21
Hanoi 20
Hong Kong 20
Barcelona 19
Changsha 19
Upper Marlboro 19
Des Moines 18
Tariceni 18
Toulouse 18
Wuhan 18
Amsterdam 17
Mumbai 17
Zhengzhou 17
Atlanta 16
Copenhagen 16
Duncan 16
Frankfurt am Main 16
Nanchang 16
Shenyang 16
Leawood 15
Piemonte 15
Baltimore 14
Chongqing 14
Delhi 14
Edinburgh 14
Totale 21.582
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? 782
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 704
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS 588
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 476
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 411
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment 404
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 369
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 360
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 341
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 309
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 301
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 300
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 298
Heart failure in patients with human immunodeficiency virus: a review of the literature. 294
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients 283
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 277
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 275
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 269
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 249
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 248
Raltegravir penetration in seminal plasma of healthy volunteers. 247
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 237
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 234
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 229
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 229
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease 227
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 220
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 215
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation 215
Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome 202
Prevalence and predictors of blood-brain barrier damage in the HAART era. 201
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 201
Descrittiva della farmacocinetica (PK) e della farmacogenetica (PG) dell'Efavirenz in una coorte di popolazione italiana 197
Acute HIV infection: Improved algorithms for HIV testing. 196
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 192
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia 182
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 178
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 175
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 175
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 173
Cardiovascular disease in HIV patients: from bench to bedside and backwards 173
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 172
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 171
West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy. 170
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 170
Failure of prophylaxis against PCP in patients with HIV infection. 167
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 163
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 162
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 161
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 160
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 159
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 159
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 157
An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients 155
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 154
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 153
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 153
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 153
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 152
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 152
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 152
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 151
Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation 151
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 150
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 149
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients 148
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 148
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 147
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 146
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 145
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 145
What do we know about tailoring treatment with tenofovir? 144
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? 144
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 143
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 143
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 142
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients 142
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients 141
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 141
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 140
Viral rebound after switch to Maraviroc-Raltegravir dual therapy 139
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject 138
Continuous intravenous infusion of enfuvirtide in an out-clinic patient with a multi resistent HIV strain and severe injection-site reactions 138
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 138
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients 137
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 137
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 137
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 136
Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers 136
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 136
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 136
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 134
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 134
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders 133
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 133
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 131
Pharmacokinetics (PKS) of rifabutin (RIF) coadministered with lopinavir/ritonavir (LPV/r) in HIV patients affected by tuberculosis (TB) 130
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 130
Population pharmacokinetics of unboosted atazanavir and influence of the pregnane -x- receptor PXR 63396C > T 129
Totale 20.504
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.960
article - articoli 0
book - libri 0
conference - conferenze 19.015
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 113.975
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.692 0 214 267 607 787 1.419 649 358 411 575 658 747
2020/20214.466 615 197 249 246 404 359 323 159 447 371 316 780
2021/20226.295 540 453 545 604 429 439 562 512 352 256 714 889
2022/20236.212 631 368 123 579 651 1.584 462 455 676 122 330 231
2023/20242.828 355 457 158 159 240 402 78 180 55 119 233 392
2024/2025136 117 19 0 0 0 0 0 0 0 0 0 0
Totale 37.696